D21-2393 subjects received a single-oral-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose.

834919-19-6

C22H25ClN6O5S

520.99

UNII-IV344R972X;D21 2393;Edoxaban 4-Carboxylic Acid;D21-2393;Edoxaban M4

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years